Confluent hepatic fibrosis as the presenting imaging sign in nonadvanced alcoholic cirrhosis
Confluent hepatic fibrosis (CHF) is usually a feature of advanced cirrhosis, while occurrence in early stage compensated cirrhosis is uncommon. We report the imaging findings of masslike CHF in a patient with previously unsuspected compensated alcoholic cirrhosis. The combination of partially wedge shape, minimal capsular retraction, and homogeneous delayed enhancement on multiphase contrast-enhanced spiral CT led to the characterization of the lesions and establishment of the diagnosis of cirrhosis. © 2004 Elsevier Inc. All rights reserved.
Showing items related by title, author, creator and subject.
Smoking as a risk factor for autoimmune liver disease: What we can learn from primary biliary cirrhosis Smyk, D. S.; Rigopoulou, E. I.; Muratori, L.; Burroughs, A. K.; Bogdanos, D. P. (2012)Primary biliary cirrhosis (PBC) is a cholestatic liver disease characterised by the immune-mediated destruction of biliary epithelial cells in small intrahepatic bile ducts. The disease is characterised by circulating ...
Heidrich, B.; Yurdaydin, C.; Kabaçam, G.; Ratsch, B. A.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Tabak, F.; Yalcin, K.; Gürel, S.; Zeuzem, S.; Cornberg, M.; Bock, C. T.; Manns, M. P.; Wedemeyer, H. (2014)Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. ...
Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort Papatheodoridis, G. V.; Manolakopoulos, S.; Touloumi, G.; Nikolopoulou, G.; Raptopoulou-Gigi, M.; Gogos, C.; Vafiadis-Zouboulis, I.; Karamanolis, D.; Chouta, A.; Ilias, A.; Drakoulis, C.; Mimidis, K.; Ketikoglou, I.; Manesis, E.; Mela, M.; Hatzis, G.; Dalekos, G. N. (2015)Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first-line antivirals remains uncertain. ...